• Passa al contenuto principale
BC

biochimica clinica

it_IT Italian
it_IT Italian en_US English
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

CONTRIBUTI SCIENTIFICI – Scientific Papers

Volume:

Biochimica Clinica 2022; 46(2) 126-133

Pubblicato on-line:

Marzo 9, 2022

DOI:

10.19186/BC_2022.011

Scarica in PDF:

Diagnostica molecolare per il SARS-CoV-2: un programma sperimentale per la Valutazione Esterna di Qualità del Centro di Ricerca Biomedica per la Qualità in Medicina di Laboratorio
Molecular diagnostic for SARS-CoV-2: an experimental External Quality Assessment Scheme

AUTORI

Luisa Galla1, Laura Sciacovelli1,2, Andrea Padoan1,3, Mario Plebani2,3
1UOC Medicina di Laboratorio, Azienda Ospedale-Università, Padova
2Centro di Ricerca Biomedica per la Qualità in Medicina di Laboratorio, Centro Specializzato della Regione Veneto, Padova
3Dipartimento di Medicina-DIMED, Università di Padova, Padova

ABSTRACT

Molecular diagnostic for SARS-CoV-2: an experimental External Quality Assessment Scheme

Introduction: External Quality Assessment (EQA) is a valuable tool to monitor and improve the analytical performances of clinical laboratories. To guarantee suitable results also during the COVID-19 pandemic, EQA scheme providers have implemented specific schemes assessing different SARS-CoV-2 diagnostic systems. This study aims to describe the results collected in an experimental EQA scheme for molecular diagnostic of SARS-CoV-2 managed by INSTAND e.V. with the collaboration of the Centre of Biomedical Research for Quality in Laboratory Medicine for Veneto Region Laboratories. Methods: the qualitative EQA results collected in three surveys (two in 2020 and one in 2021) for 18 samples total, have been summarized to identify the percentage of laboratory results per sample. Control samples were provided by NationalesKonsiliarlaboratorium fur Coronaviren of Berlin. Results: even though the average of the participating laboratories strongly decreased between surveys, a good agreement was found among results (95% to 99.8%). A totally of 0.2% – 4% of incorrect results and 0% – 1.1% of indeterminate results were reported. In addition, the sequencing analysis and the point mutations analysis, included in the last analyzed survey, revealed a good agreement between participating laboratories with an overall score from 74.8% to 89.6% for the sequencing and from 90.65% to 95.33% for the point mutations, respectively. Conclusions: the EQA programs are a fundamental quality assurance tool to evaluate the laboratory performance and to appreciate the State-of-the-Art of the different diagnostic systems used by participating laboratories. The need for an EQA scheme for every test performed in the laboratory is mandatory to guarantee patient safety.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967